Drugs / VAC85135
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05444530 | Jul 2022 → Jun 2025 | myeloproliferative neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAC85135 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05444530 ↗ |
| Modality | Vaccine | “A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab” NCT05444530 ↗ |
| Route | Intramuscular | “Participants will receive VAC85135 as IM injection.” NCT05444530 ↗ |